title: Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
abstract: Children account for 7%-20% of cutaneous leishmaniasis cases in Iran, but there are few safety data to guide pediatric antiparasitic therapy. We evaluated the clinical and laboratory tolerance of the systemic pentavalent antimonial compound meglumine antimoniate, in 70 Iranian children with cutaneous leishmaniasis. Adverse effects were similar to those seen in adults.
authors.affiliation: Cutaneous Leishmaniasis Research Center, Qaem Hospital, School of Medicine.
authors.forename: Pouran
authors.initials: P
authors.lastname: Layegh
authors.affiliation: Dermatology Department, Qaem Hospital, School of Medicine, Mashhad University of Medical Sciences.
authors.forename: Zeinab
authors.initials: Z
authors.lastname: Khademi
authors.affiliation: Department of Epidemiology and Statistics, Mashhad University of Medical Sciences, Iran.
authors.forename: Monavar
authors.initials: M
authors.lastname: Afzal Aghaee
authors.affiliation: Cutaneous Leishmaniasis Research Center, Qaem Hospital, School of Medicine.
authors.forename: Toktam
authors.initials: T
authors.lastname: Moghiman
mesh_terms: D000293:Adolescent; D000981:Antiprotozoal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007492:Iran; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D008536:Meglumine / Q000009:adverse effects* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine
keywords: adverse effects; children; cutaneous leishmaniasis; meglumine antimoniate